Tolvaptan use tied to changes in mineral metabolism parameters and increased BMD in polycystic kidney disease
Switzerland: Chronic treatment with Tolvaptan is tied to an increased femoral bone mineral density (BMD), and remarkable changes in both acid-base parameters and mineral metabolism in patients with...